Bio-techne Corp · NASDAQ:TECH
Bio-techne — Investor Presentation (June 2024)
26 slides from Bio-techne's investor presentation, June 2024
Slide 1: Purposeful Innovation Leads to Better Answers
J U N E 2 0 2 4 Purposeful Innovation Leads to Better Answers Bio-Techne Corporate Presentation Confidential | © 2024 Bio-Techne®. All rights reserved. | 1
Slide 2: Safe Harbor Cautionary Statements
Safe Harbor CAUTIONARY STATEMENTS This presentation contains “forward-looking “expect,” “forecast,” “would,” “estimate,” “will,” or We undertake no obligation to update any statements” within the meaning of the federal similar references to future periods. Forward- forward-looking statement, whether
Slide 3: Our Mission and Vision
Our Mission To improve the quality of life by catalyzing advances in science and medicine. Vision Together, we unlock the possibilities of science. Confidential | © 2024 Bio-Techne®. All rights reserved. | 3
Slide 4: A Sustainable Future
A Sustainable Future PUBLISHED OUR THIRD CORPORATE SUSTAINABILITY REPORT Environmental Social Governance Continued progress toward Diverse and inclusive workplace: Board includes: sustainability at largest manufacturing site: • ISO 14001 Certification • 49% of global workforce are female • Deep scie
Slide 5: Business Overview
PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS Business Overview Confidential | © 2024 Bio-Techne®. All rights reserved. | 5
Slide 6: Portfolio of Proven Products $1.1B
CONSUMABLES-FOCUSED President & CEO Portfolio of Proven Products Kim Kelderman Product Portfolio Instruments Headquarters Services Protein Sciences Segment Minneapolis, MN 10% 7% Royalties 2% Number of Employees Proteins Antibodies Immunoassays ~3,100 Cell & Gene Proteomic Analytical $1.1B Worldwide
Slide 7: FY23 Revenue Breakdown ($1.1B)
FY23 Revenue Breakdown ($1.1B) Segments & Product End Markets Markets Geographies 74% Protein Sciences 26% Diagnostics & Segment Genomics Segment Spatial Biology 13% 9% Liquid Distributors Biopsy 24% 5% & MDx EMEA 12% Core 50% 17% Core 44% Diagnostics 60% Pharma/ Americas Biotech 10% China 23% 20% 6
Slide 8: Large Addressable End Markets: ~$27B
Large Addressable End Markets: ~$27B Market Historic 5-Yr Bio-Techne End Markets Market Size Growth Rate Bio-Techne CAGR Market Penetration Core Products* ~$6B Mid-Single Digit 7% ~10% Proteomic Analytical ~$3B Low-Double Digit 19% ~10% Instruments Cell & Gene Therapy ~$4B >20% 50% ~2% Spatial Biolo
Slide 9: Portfolio Positioned for Global Megatrends
Portfolio Cell Culture & Gene Therapy Positioned Healthy for Global Liquid Biopsy & Aging Megatrends Molecular Dx Spatial Biology Precision Medicine Proteomic Assays & Analytics Breakthrough AI Models Multiomic Technologies CORE PRODUCTS Automation MEGATRENDS Confidential Confidential || © © 2024 20
Slide 10: Strategic Pillars
Strategic Pillars Grow & Capitalize on Market Expansion Deliver Leverage High Potential Through Innovation Best-in-Class the Core Markets & Acquisition Customer Experience Develop People Through a Transformative Culture Confidential | © 2024 Bio-Techne®. All rights reserved. | 10
Slide 11: Core Products
Core Products Addressable Market: ~$6B Diagnostic Small Controls & Proteins Antibodies Immunoassays Molecules Calibrators Market Growth: Mid-Single Digit Bio-Techne Market Share: ~10% Bio-Techne 5 Year Trailing CAGR: ~7% Leading portfolio Largest Wide range of Most cited Broad menu of Brands of high
Slide 12: What Makes Our Protein & Antibody Content Special
What Makes Our Protein & Antibody Content Special BEST IN CLASS CONTENT IS OUR ENGINE Choice Confidence Continued Innovation • Stringent quality standards and • Scaling of factories & yields dedicated GMP facilities • Over 6,000 RUO & • Pairing AI (alpha fold) and new techniques • Testing every Prot
Slide 13: Our Expansion Into Growth Verticals
Our Expansion Into Growth Verticals Confidential | © 2024 Bio-Techne®. All rights reserved. | 13
Slide 14: Core Products Enable Growth Verticals
Core Products Enable Growth Verticals DELIVERING COMPREHENSIVE WORKFLOW SOLUTIONS Proteomic Analytics Core Products Cell Culture & Gene Therapy Antibodies Proteins Immunoassay Spatial Biology Calibrators & Controls Small Molecules Liquid Biopsy & Molecular Dx Confidential | © 2024 Bio-Techne®. All r
Slide 15: Proteomic Analytical Instruments
Proteomic Analytical Instruments Addressable Market: >$3B Market Growth: Low-Double Digit Simple Western Biologics Bio-Techne Market Share: Only fully automated Bioprocessing instrument western blot solution for for protein purity, charge ~10% protein identification and and identity analysis as quan
Slide 16: Expanding Proteomic Analytical Instrument Applications & Markets
Expanding Proteomic Analytical Instrument Applications & Markets Biologics Simple Western Simple Plex Legacy Application Legacy Application Legacy Application • Protein purity, charge and identity • Fully automated western blot solution • Automated multiplexing ELISA solution for research use Expand
Slide 17: Cell & Gene Therapy
Cell & Gene Therapy Total Addressable Market: ~$4B Cell Culture Regenerative Medicine Immune Cell Therapy Market Growth: >20% Bio-Techne Market Share: G-Rex Cultrex ECMs ~2% Bio-Techne 5 Year RUO Media & Supplements Trailing CAGR: GMP Media GMP Proteins RUO Small ~50% Molecules Brands GMP IL-2, IL-7
Slide 18: Aseptic Immune Cell Therapy Manufacturing Solution
Aseptic Immune Cell Therapy Manufacturing Solution Clinically TcBuster Proven GMP Non-viral Media Gene Engineering GMP Closed Process Cytokine G-Rex Sized GMP Delivery * Cytokines *Bio-Techne currently owns 20% equity investment in Wilson Wolf with an agreement to acquire the remainder of the compan
Slide 19: Spatial Biology
Spatial Biology Total Addressable Market: Fully Automated Spatial ~$5B Multiomic Workflow Market Growth: Low-Double Digit Bio-Techne Market Share: >2% Bio-Techne 5 Year Tissue Pre- Reagent Loading Probe Automated RNA Automated Protein Processing Slide Loading Hybridization + Detection Detection Trai
Slide 20: Our Vision for Powering Multiomic Spatial Biology
Our Vision for Powering Multiomic Spatial Biology Diseases Involving the Immune System (Cancer/IO, Inflammation, Auto-Immunity) Pathology Immune Cell Cell Function Disease Identification Cytokine Cell and Gene Markers Chemokine Pathology Protein biomarkers Therapies with clinical utility CAR T, TCR
Slide 21: Liquid Biopsy & Molecular Diagnostics
Liquid Biopsy & Molecular Diagnostics Total Addressable Market: Screening Diagnosis Monitoring ~$9B Many patients Frequent tests Market Growth: Fragile X CFTR Fragile X C9orf72 BCR-ABL (CML) Low-Double Digit Current SMA TRIO SMA HTT Products CFTR DMPK Bio-Techne Market Share: ~
Slide 22: ExoLution Plus exoRNA
Bringing Exosomes to the Many liquid biopsy (LBx) products use cell-free DNA (cfDNA) or circulating tumor cells (CTCs). Forefront of Liquid Biopsy Exosomes are a more abundant and a richer source of biological information BRAF Key Properties CTC cfDNA Exosomes copies/mL 64000 Analyte RNA+DNA DNA onl
Slide 23: Translating an M&A Strategy into Financial Results
Translating an M&A Strategy into Financial Results Confidential | © 2024 Bio-Techne®. All rights reserved. | 23
Slide 24: Successful Acquisition Strategy Has Led to Sustained & Accelerated Growth
Successful Acquisition Strategy Has Led to Sustained & Accelerated Growth Pre-FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 1,200 REVENUE ($ MILLION) 1,000 800 600 400 200 0 Pre-FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 ACQUISITION STRATEGY HAS CREATED AN ORGANIC GROWTH ENGINE
Slide 25: Business Positioned for Long Term Growth
Business Positioned Proteomic Analytics for Long Term Growth MARKET HISTORIC 5-YR ACQUISITIONS MARKET GROWTH BIO-TECHNE SIZE RATE CAGR Core Cell & Core P R O T E I N S C I E N C E S Products Products Gene Therapy S E G M E N T Proteomic Analytics Cell & Gene Therapy Spatial Biology Spatial D I A G N
Slide 26: Confidential | © 2024 Bio-Techne ® . All rights reserved. | 26
Confidential | © 2024 Bio-Techne®. All rights reserved. | 26